Related Experiment Video
Updated: Feb 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Mutation of TGFβ-RII eliminates NSAID cancer chemoprevention
Juana Martín-López1, Pierluigi Gasparini1, Kevin Coombes2
1Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Abstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) exhibit anti-neoplastic (chemoprevention) activity for sporadic cancers and the hereditary cancer predisposition Lynch syndrome (LS/HNPCC). However, the mechanism of NSAID tumor suppression has remained enigmatic. Defects in the core mismatch repair (MMR) genes MSH2 and MLH1 are the principal drivers of LS/HNPCC. Previous work has demonstrated that the villin-Cre (VpC-Msh2) mouse is a reliable model for LS/HNPCC intestinal tumorigenesis, which is significantly suppressed by treatment with the NSAID aspirin (ASA) similar to human chemoprevention. Here we show that including a TGFβ receptor type-II (Tgfβ-RII) mutation in the VpC-Msh2 mouse (villin-Cre-RII ) completely eliminates NSAID tumor suppression. These results provide strong genetic evidence that TGFβ signaling and/or effectors participate in NSAID-dependent anti-neoplastic processes and provide fresh avenues for understanding NSAID chemoprevention and resistance.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) suppress tumors in Lynch syndrome models. However, blocking TGFβ signaling completely eliminates this chemoprevention effect, revealing a key mechanism.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) show chemoprevention effects against sporadic and hereditary cancers, including Lynch syndrome (LS/HNPCC).
- The precise mechanism underlying NSAID-mediated tumor suppression remains unclear.
- Defects in mismatch repair (MMR) genes MSH2 and MLH1 are primary causes of LS/HNPCC.
Purpose of the Study:
- To investigate the role of TGFβ signaling in NSAID-dependent chemoprevention of intestinal tumors in a mouse model of Lynch syndrome.
- To elucidate the genetic pathways involved in NSAID tumor suppression.
Main Methods:
- Utilized a villin-Cre-Msh2 (VpC-Msh2) mouse model for LS/HNPCC intestinal tumorigenesis.
- Introduced a TGFβ receptor type-II (Tgfβ-RII) mutation into the VpC-Msh2 model, creating the villin-Cre-RII mouse.
- Assessed the impact of aspirin (ASA) treatment on tumor suppression in both mouse models.
Main Results:
- Aspirin (ASA) significantly suppressed intestinal tumorigenesis in the VpC-Msh2 mouse model, mirroring human chemoprevention.
- The presence of the Tgfβ-RII mutation in the villin-Cre-RII mouse completely abolished the tumor-suppressive effects of ASA.
- This indicates a critical role for TGFβ signaling in NSAID-mediated anti-neoplastic activity.
Conclusions:
- TGFβ signaling and/or its effectors are essential components of NSAID-dependent anti-neoplastic processes.
- These findings offer new insights into the mechanisms of NSAID chemoprevention and resistance.
- The study highlights potential therapeutic targets for enhancing cancer chemoprevention strategies.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Mutation, Gene Flow, and Genetic Drift
Viral Mutations
Mutations in Microorganisms

